After Leerink Partners and RBC Capital gave Anthem (NYSE: ANTM) a Buy rating last month, the company received another Buy, this time from Credit Suisse. Analyst A.J. Rice maintained a Buy rating on Anthem yesterday and set a price target of $355.00. The company’s shares closed last Thursday at $278.53.
According to TipRanks.com, Rice is a 4-star analyst with an average return of 6.7% and a 60.4% success rate. Rice covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Community Health, and Encompass Health.
Currently, the analyst consensus on Anthem is a Moderate Buy with an average price target of $333.63, which is a 20.7% upside from current levels. In a report released today, Leerink Partners also maintained a Buy rating on the stock with a $345.00 price target.
See today’s analyst top recommended stocks >>
Anthem’s market cap is currently $70.99B and has a P/E ratio of 14.30. The company has a Price to Book ratio of 159.59.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anthem is one of the largest private health insurance organizations nationwide, providing medical benefits to roughly 40 million medical members. The company offers employer, individual, and government-sponsored coverage plans. Anthem differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states.
